Canopy Growth reported a 6% increase in net revenue to $285 million for FY26, driven by strong performance in Canadian medical and adult-use cannabis segments. The company achieved $6 million in annualized cost synergies from the MTL Cannabis acquisition and targets $10 million in run-rate savings within 18 months. With a strengthened balance sheet showing a net cash position of $131 million, management is confident in achieving positive adjusted EBITDA in fiscal 2027.

In the latest trading session, Canopy Growth Corporation (CGC) closed at $0.94, marking a +2.57% move from the previous day.

Canopy Growth (CGC) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock

Canopy Growth (NASDAQ:CGC) stays in focus as today’s market setup highlights cannabis products, brand strategy, cost discipline and regulatory sensitivity amid tighter financial conditions and selective trading in rate-sensitive industries.

Two long-standing issues continue to weigh on this cannabis stock.

Canopy Growth Corporation (CGC) reached $0.94 at the closing of the latest trading day, reflecting a +1.15% change compared to its last close.

Canopy Growth Corporation operates across Canada and selected international markets with adult-use and medical cannabis products providing company-specific context within S&P TSX Composite Index and.

Canopy Growth Corporation has announced a broadening of its medical cannabis portfolio in Australia across its Spectrum Therapeutics, Spectrum Therapeutics Reserve, 7ACRES, Tweed and Twd.…

Canopy Growth (NASDAQ:CGC) is in focus today as trades actively as cannabis shares remain highly sensitive to sector headlines, with sector conditions and company execution shaping the market narrative.